treatment technologies such as anti-vascular endothelial growth factor (anti-VEGF) and photodynamic therapy (PDT) are mainly for WAMD. So burden of disease (BOD) of WAMD is gradually increasing and causes for more concern. We intend to make an empirical study to explore BOD of WAMD in China, providing references for health care-related decision making.
Objectives:
To explore the burden of wet age-related macular degeneration (WAMD) in China.
Methods: Multi-center, retrospective and cross-sectional investigation was adopted. Beijing, Chengdu, Guangzhou and Shanghai were selected as sample cities, and several hospitals were involved in each city.
Patients were selected according to inclusive and exclusive criteria, and they were divided into 5 groups, i.e., photodynamic therapy (PDT), photocoagulation therapy (PCT), surgery therapy (ST1), joint therapy (JT) and support therapy (ST2) groups. Direct cost, indirect cost and burden of disease (BOD) were studied.
Results: 417 eligible patients were acquired, males and females accounted for 51.32% and 48.68% Conclusions: The burden of WAMD is relatively high in China, it should be paid more attention by stakeholders. Although new diagnostic and therapeutic methods may raise direct medical cost, they may reduce total burden of WAMD more, which shows the advantage for new technologies. WAMD guideline will be beneficial to both patients and direct medical cost management. Targeting young patients as a priority of intervention will help to reduce total social burden of WAMD.
